References
- Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd Edition. Cephalalgia. 2018;38:1–211.
- GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954–976.
- Lipton RB, Manack Adams A, Buse DC, et al. A comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) study and American Migraine Prevalence and Prevention (AMPP) study: demographics and headache-related disability. Headache. 2016;56(8):1280–1289.
- Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52(10):1456–1470.
- Centre for Reviews and Dissemination (CRD) [Internet]. University of York. Systematic reviews: CRD’s guidance for undertaking reviews in health care. January 2009. [cited October 23, 2018]. Available from: https://www.york.ac.uk/media/crd/Systematic_Reviews.pdf
- Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ. 1996;313(7052):275–283.
- British Association of the Study of Headache [Internet]. Guidelines for all healthcare professionals in the diagnosis and management of migraine, [cited August 4, 2019]. Available from: https://www.bash.org.uk/guidelines/.
- NICE. Botulinum toxin type A for the prevention of headaches in adults with chronic migraine. [cited May 2, 2019]. Available from: https://www.nice.org.uk/guidance/ta260.
- Royle P, Cummins E, Walker C, et al. Evidence review group report: Botulinum toxin type A for the prophylaxis of headaches in adults with chronic migraine, 2012. [cited August 22, 2019]. Available from: https://www.nice.org.uk/guidance/ta260/documents/migraine-chronic-botulinum-toxin-type-a-evidence-review-group-report2
- Batty AJ, Hansen RN, Bloudek LM, et al. The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK. J Med Econ. 2013;16(7):877–887.
- SMC [Internet]. SMC advice: botulinum toxin A (Botox) 2011. [cited October 23, 2018]. Available from: https://www.scottishmedicines.org.uk/files/advice/botulinum_toxin_type_A_Botox_FINAL_MARCH_2011_AMENDED_22.03_for_website.pdf
- SMC [Internet]. SMC advice: botulinum toxin A (Botox) 2013. [cited October 23, 2018]. Available from: https://www.scottishmedicines.org.uk/files/advice/botulinum_toxin_type_A_Botox_RESUBMISSION_Final_March_2013_for_website.pdf
- SMC [Internet]. SMC advice: botulinum toxin A (Botox) 2017. [cited October 23, 2018]. Available from: https://www.scottishmedicines.org.uk/files/advice/botulinum_toxin_A_BOTOX_2nd_Resub_FINAL_Jan_2017_for_website.pdf
- SMC [Internet]. SMC advice: topiramate (Topamax) 2006. [cited October 23, 2018]. Available from: https://www.scottishmedicines.org.uk/files/topiramate_Topamax_297_06.pdf
- Brown JS, Papadopoulos G, Neumann PJ, et al. Cost-effectiveness of migraine prevention: the case of topiramate in the UK. Cephalalgia. 2006;26(12):1473–1482.
- Lipton RB, Porter JK, Shah N, et al. A comparison of approaches to model migraine day frequency in migraine. Cephalalgia. 2017;37:102–103.
- Di Tanna GL, Porter JK, Lipton RB, et al. Migraine day frequency in migraine prevention: longitudinal modelling approaches. BMC Med Res Methodol. 2019;19(1):20.
- Mahon R, Vo P, Cooney P, et al. A model concept for assessing the cost-effectiveness of preventive migraine treatments. 12th European Headache Federation Congress. 2018 Sep 28–30; Florence, Italy. J Headache Pain. 2018;19(Suppl1)80:108.
- Doane MJ, Gupta S, Vo P, et al. Associations between headache-free days and patient-reported outcomes among migraine patients: a cross-sectional analysis of survey data in Europe. Pain Ther. 2019; Dec8(2):203–216.
- Martelletti P, Schwedt TJ, Lanteri-Minet M, et al. My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. J Headache Pain. 201819(1):115.
- Hollier-Hann G, Curry A, Onishchenko K, et al. Updated cost-effectiveness analysis of onabotulinumtoxinA for the prevention of headache in adults with chronic migraine who have previously received three or more preventive treatments in the UK. J Med Econ. 2020;23(1):113–123.